Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of LY3526318 in Healthy Participants
NCT04682119Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2020
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of LY3526318 in chronic pain (4 arms), sponsored by Eli Lilly and Company. Primary endpoints: Area Under the Concentration Time Curve From Time 0 to Infinity at 96 hours, Maximum Observed Drug Concentration at 96 hours and 1 more. Started Dec 2020; status: completed.
02
Drugs
LY3526318
03
Conditions
chronic pain
Beyond the preview
Go deeper on NCT04682119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04682119.